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Abstract: Glucagon-like peptide-1 (GLP-1) is a hormone secreted from enteroendocrine L cells 
of the intestine in response to food. Exogenous GLP-1 administration at pharmacological doses 
results in many effects that are beneficial for treating type 2 diabetes, these include: (1) an 
increase in insulin secretion from β cells; (2) a suppression of glucagon secretion from α cells 
in the presence of hyperglycemia but not hypoglycemia; (3) a delay in gastric emptying and gut 
motility which in turns delays absorption of ingested nutrients and dampens post-prandial glucose 
excursion; and (4) an increase in the duration of postprandial satiety therefore suppressing appetite 
and decreasing food intake which eventually leads to weight loss. However, GLP-1 is subject 
to rapid enzymatic degradation, and therefore, not suitable for long-term treatment. A synthetic 
enzyme-resistant GLP-1 receptor agonist that reproduces the biological effects of GLP-1 is in 
use and more are under development. This review aims at providing a summary of the properties 
of GLP-1 and the development of GLP-1-based therapies for treatment of diabetes.
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Introduction
what are incretins?
The incretin effect describes the augmentation in insulin secretion that occurs in 
response to oral glucose compared to intravenous glucose.1–3 Incretins, therefore by 
definition, are gut-derived factors that stimulate insulin secretion from β cells after 
eating. The two hormones that fulfill criteria as incretins are glucose-dependent insu-
linotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
GIP is a 42-amino acid peptide synthesized and released from enteroendocrine 
K cells mostly located in the duodenum and upper jejunum.4 GLP-1, a product of 
the proglucagon gene, exists in two bioactive forms, GLP-1 (7-36) amide and GLP-1 
(7–37), with GLP-1 (7–36) comprising up to 80% of the GLP-1 in circulation.5 It is 
released from enteroendocrine L cells dispersed throughout the gastrointestinal tract.6,7 
Together, the insulinotropic effect of GLP-1 and GIP accounts for up to 60% of the 
insulin secreted after a meal in healthy humans and plays a very important role in 
postprandial glucose homeostasis.8
In patients with type 2 diabetes mellitus (T2DM), the ability of exogenous GIP 
and GLP-1 to stimulate insulin secretion is diminished by 54% and 29%, respectively, 
when compared to healthy subjects. However, the glucose lowering effect of GLP-1 
is relatively preserved while that of GIP is absent.9–11 Therefore, development of 
therapeutic strategies for T2DM has focused on GLP-1 and not GIP.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 38
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Physiology of GLP-1
Fat and carbohydrate-rich meals are the primary physiological 
stimuli to GLP-1 secretion from enteroendocrine cells.12 
Recently, artificial sweeteners, such as sucralose, have 
also been shown to induce GLP-1 secretion from L cells.13 
Although GLP-1 has been found in taste buds and brain 
tissues, the majority of the GLP-1 measured in peripheral 
blood is synthesized in L cells.7
In healthy subjects, fasting levels of plasma GLP-1 range 
from 5–10 pmol/L and increase by two- to three-fold after 
meal ingestion.14 GLP-1 levels peak about 20 min after oral 
glucose administration and about 60 to 90 min after mixed 
meal ingestion, and the levels gradually decline toward 
fasting levels thereafter.15,16 GLP-1 stimulates insulin 
secretion in a glucose concentration dependent manner; its 
insulinotropic effect is lost at plasma glucose concentration 
below 4.3 mmol/L (77 mg/dL).17
In earlier studies, patients with long-standing T2DM and 
poor glycemic control (HbA1c ∼9.2%) were noted to have 
deficient GLP-1 secretion.18,19 Recent studies have shown that 
GLP-1 levels are similar among subjects with mild T2DM 
(HbA1c ∼6.8%), impaired glucose tolerance, and normal 
glucose tolerance.15,16 Therefore, GLP-1 secretion in patients 
with T2DM appears to depend on their glycemic status, their 
medication intake, and other hormonal and metabolic abnor-
malities associated with worsening glycemic control.16
GLP-1 has a short half-life of 2 min because it is rapidly 
degraded by dipeptidyl peptidase 4 (DPP 4) and neutral endo-
peptidase (NEP) 24.11.20–22 DPP 4 cleaves the N-terminal 
dipeptides (His7–Ala8) from GLP-1 (7–36) and renders the 
resulting major metabolite GLP-1 (9–36) insulinotropically 
inactive.20,23 NEP 24.11, a membrane-bound zinc metallo-
peptidase, also degrades GLP-1 at potentially six cleavage 
sites.21 High levels of NEP 24.11 are found in the kidney, 
and GLP-1 and its metabolites are rapidly cleared through 
the kidneys.24
The action of GLP-1 is mediated through the glucagon-
like peptide-1 receptor (GLP-1R), a seven-member 
trans-membrane G protein-coupled receptor.25 GLP-1R is 
expressed in a variety of tissues including pancreatic β cells, 
hypothalamus, hippocampus, area postrema and various 
other parts of the brain, as well as stomach, heart, intestine, 
and kidney.26
GLP-1-based therapy in T2DM
Regardless of the post-prandial levels of GLP-1 in T2DM, 
the insulin response to GLP-1 is still defective. The response 
of β cells to exogenously administered GLP-1 was noted to 
be three to five times lower in patients with T2DM when 
compared to healthy subjects.11,27 Despite the diminished 
response of β cells to exogenous GLP-1, overnight 
intravenous infusion of GLP-1 in patients with T2DM was 
able to lower fasting and post-prandial plasma glucose to 
near-normal levels, to improve β-cell function, and to restore 
first-phase insulin secretion.28
To examine the effect of long-term GLP-1 treatment 
in patients with T2DM, continuous subcutaneous GLP-1 
infusion was given for six and 12 weeks using an infusion 
pump in two separate studies.29–31 Both studies showed 
that GLP-1 infusion clearly improved β-cell function 
and improved insulin sensitivity. A subset of subjects in 
the 12-week infusion study had frequent blood sampling 
performed after six weeks of therapy and the results showed 
significant improvement in insulin pulse mass and pulsatile 
insulin secretion.31
Exogenous GLP-1 administration at pharmacological 
doses also has several noninsulinotropic effects that 
are beneficial for treating T2DM. With exogenous 
GLP-1, glucagon secretion from α cells was suppressed 
in the presence of hyperglycemia and euglycemia but 
not hypoglycemia. The suppression of glucagon leads to 
improved hepatic insulin resistance and glycemic control in 
T2DM.17,32 Exogenous GLP-1 also delays gastric emptying 
and gut motility and these effects slow absorption of ingested 
nutrients and dampen post-prandial glucose excursion in 
patients with T2DM.33 Exogenous GLP-1 also increases the 
duration of postprandial satiety, decreases energy intake and 
suppresses appetite; leading to less food being eaten and 
eventually weight loss in most people.29,34,35
Most hypoglycemic agents work by either attempting 
to increase insulin secretion from β cells (sulfonylureas, 
meglitinides) or increasing peripheral insulin sensitivity 
(biguanides, thiazolidinediones). None of them actually 
targets the root cause of T2DM; deteriorating β-cell 
function and mass. In addition to stimulating insulin secre-
tion and suppressing glucagon secretion, GLP-1 has other 
pleiotropic effects in the pancreas. Animal studies have 
suggested that chronic exogenous GLP-1 administration 
has the ability to increase islet size, enhance β-cell 
proliferation, inhibit β-cell apoptosis, and regulate islet 
growth.36,37 These trophic effects on β cells have not been 
tested in humans as there is no direct in vivo measure of 
human β-cell mass available.
Using indirect measures of β-cell function, one study 
showed that short-term (12 hours) GLP-1 infusion improved 
the ability of β cells to sense and respond to glucose in patients Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 39
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with impaired glucose tolerance.38 Overnight GLP-1 infusion 
also improved first- and second-phase insulin secretion in 
patients with T2DM.28 Six-week infusion of GLP-1 in patients 
with T2DM showed improvement in insulin sensitivity 
and β-cell function as measured by glucose utilization and 
first- and second-phase C-peptide response during hyperin-
sulinemic euglycemic clamp.29 If the trophic effects seen in 
rodents are indeed present in humans, treatment with GLP-1 
will have tremendous implications in the field of T2DM as it 
directly addresses one of the fundamental defects in T2DM, 
that is, β-cell failure.
Collectively, the biological effects of exogenous GLP-1 – 
increasing insulin secretion from β cells, suppressing gluca-
gon secretion from α cells, decreasing post-prandial glucose 
excursion through delay in gastric emptying, increasing post-
prandial satiety, and possibly enhancing the trophic effects 
on human β cells – make GLP-1 receptor-based therapy a 
highly desirable treatment option for T2DM. However, the 
short half-life of GLP-1 (2 min) renders the native GLP-1 
peptide impractical for clinical use. Two obvious options 
for GLP-1 receptor-based therapies are: (1) GLP-1 analogs 
with longer half-lives and full efficacy at the GLP-1 receptor 
(GLP-1R agonists); and (2) agents such as DPP 4 inhibitors 
that can increase plasma levels of endogenous GLP-1. In this 
review, we will focus on the GLP-1R agonists. So far, no 
headway has been made on developing drugs to specifically 
increase endogenous secretion of GLP-1, though a drug in 
common use for T2DM, metformin, does cause about a two-
fold increase in GLP-1 secretion.39
GLP-1 r agonists
As mentioned earlier, GLP-1 has a half-life of only about 
2 min because it is rapidly degraded by DPP 4 and NEP 
24.11. To develop GLP-1R agonists with longer half-lives, 
various modifications of GLP-1 at His7, Ala8, or Glu9 have 
been attempted so as to prevent DPP 4 from cleaving the first 
two N-terminal amino acids (His7, Ala8) of native GLP-1.40 
Additional mid-chain modifications of the GLP-1 peptide 
to prevent hydrolysis by NEP 24.11 are also being studied. 
Other technologies that allow gradual drug delivery at a 
controlled rate are also being investigated. This review will 
summarize the GLP-1R agonists that have clinical efficacy 
data published in peer-reviewed journals and presented at 
major scientific meetings.
Exenatide
Exenatide (synthetic exendin-4) is the only GLP-1R agonist 
currently approved by regulatory agencies as an adjunct 
therapy for patients with T2DM who are not achieving 
satisfactory glycemic control using other hypoglycemic 
agents. Exendin-4 is a 39-amino acid peptide produced in the 
salivary glands of the Gila monster (Heloderma suspectum) 
(Figure 1). It has 53% amino acid homology to full-length 
GLP-1 and binds more avidly than GLP-1 to the GLP-1R.25 
There appears to be no specific exendin-4 receptor; the 
effects of exendin-4 are expressed through the known GLP-1 
receptor. Exendin-4 has a Gly8 in place of an Ala8 of the 
N-terminus, and therefore, is not a substrate for DPP 4. In 
addition, it lacks some of the target bonds for NEP 24.11, and 
its secondary and tertiary structures may also prevent NEP 
24.11 hydrolysis, thus leading to a prolonged half-life.
Pharmacology
Since exenatide is a peptide, it must be administered 
subcutaneously. After its subcutaneous administration, exena-
tide reaches a maximum plasma concentration in 2.1 hr, and 
the mean half-life ranges from 3.3 to 4 hrs.41 It can be detected 
for up to 15 hrs in the plasma after subcutaneous injection and 
its biological effect remains up to at least 8 hrs after dosing.41 
In a nonclinical study, it was shown to be eliminated by the 
kidneys through glomerular filtration.42
Efficacy studies
Three randomized, placebo-controlled, double or triple-blind, 
30-week clinical trials examined the efficacy of exenatide in 
subjects with T2DM not achieving adequate glycemic control 
on metformin and/or sulfonylurea (Table 1).43–45 Patients 
were randomized to placebo, exenatide 5 µg twice daily, or 
10 µg twice daily as adjuvant treatment to sulfonylurea, 
metformin, or sulfonylurea/metformin. In all three studies, 
exenatide significantly reduced HbA1c in the treatment 
groups with exenatide 10 µg twice daily lowered HbA1c by 
0.8%–0.9%; exenatide 5 µg twice daily lowered HbA1c by 
0.4%–0.6%; while placebo increased HbA1c by 0.1%–0.2%. 
In the metformin/exenatide10 µg twice daily treatment arm, 
41% of patients achieved HbA1c  7% and a mean weight 
loss of 2.8 kg. In the sulfonylurea/exenatide 10 µg twice daily 
treatment arm, 41% of patients achieved HbA1c of  7% and 
a mean weight loss of 1.6 kg. In the metformin/sulfonylurea/
exenatide 10 µg twice daily treatment arm, 34% of patients 
achieved HbA1c of  7% and a mean weight loss of 1.6 kg.
The above three trials and their open-label extensions 
were folded into one open-ended, open label trial.46 Results 
from this three-year follow-up study showed that after 
treating with exenatide 10 µg twice daily, the 1.0% reduction 
in HgbA1c was sustained; 46% of the patients maintained a Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 40
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HbA1c of  7%; and progressive weight loss was noted with 
a net-loss of 5.3 kg at the end of three years (Table 1).46
The efficacy of exenatide (10 µg twice daily) added 
to rosiglitazone (4 mg/day) alone or pioglitazone 
(30 mg/day) alone, or in combination with metformin 
was examined in a randomized, double-blind, placebo-
controlled trial for 16 weeks (Table 1). When compared to 
placebo, addition of exenatide to thiazolidinediones (TZD) 
in the presence or absence of metformin reduced HbA1c by 
0.9%, mean fasting plasma glucose by 1.6 mmol/L, and 
body weight by 1.8 kg. However, only 71% of subjects 
given exenatide as compared with 86% of subjects in 
the placebo group completed the study where many 
(14%) discontinued the study because of gastrointestinal 
symptoms from exenatide.47
Exenatide therapy was also compared to insulin therapy 
as add-on to oral hypoglycemic agents. In a 26-week 
multicenter, open-label, randomized, controlled trial, subjects 
with T2DM whose glycemia was not adequately controlled 
by metformin and/or sulfonylurea were randomized to either 
adding exenatide 10 µg twice daily or insulin glargine daily 
(titrating to fasting blood glucose of 5.6 mmol/L). At the 
end of 26 weeks, both groups achieved similar improvement 
in glycemic control (1.1% reduction in HbA1c). However, 
the exenatide group had better post-prandial glucose control 
while the glargine group had lower fasting plasma glucose 
levels. An average weight loss of 2.3 kg was noted with 
exenatide, and an average weight gain of 1.8 kg was noted 
with glargine. The drop out rate was 19.4% with exenatide 
(6% due to nausea) and 9.7% with glargine.48
Exenatide was also compared to biphasic insulin aspart 
(30% rapid-acting insulin aspart) in a 52-week, randomized, 
open-label trial in patients with T2DM whose glycemia was 
not optimally controlled with metformin and sulfonylurea.49 
The efficacy of exenatide was comparable to biphasic insulin 
aspart with similar reduction in HbA1c (1% versus 0.9%) and 
comparable reduction in fasting plasma glucose (1.8 versus 
1.7 mmol/L). The exenatide group had weight reduction of 
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2.5 kg while the biphasic insulin group had a weight increase 
of 2.9 kg.
In a 24-week, randomized, double-blind, placebo-
controlled, parallel-group study, patients with T2DM naïve 
to hypoglycemic agents and not optimally controlled with 
diet and exercise, were randomized to exenatide 5 µg twice 
daily, exenatide 10 µg twice daily, or placebo twice daily. 
Significant reductions in HbA1c of 0.7% and 0.9% were 
noted in the exenatide 5 µg and 10 µg twice daily groups, 
respectively, compared to reduction of 0.2% in the placebo 
group. A similar significant reduction in fasting serum 
glucose of 1.0 mmol/L was noted in the exenatide 5 µg and 
10 µg twice daily groups, respectively, compared to a reduc-
tion of 0.3 mmol/L in the placebo group. Significant reduction 
in weight was also observed in the exenatide 5 µg and 10 µg 
twice daily groups; 2.8 kg and 3.1 kg, respectively, compared 
to 1.4 kg reduction in the placebo group.50 The indication of 
using exenatide as monotherapy is currently under review by 
the United States Food and Drug Administration (FDA).51
Safety and tolerability
A meta-analysis based on randomized controlled trials was 
conducted to evaluate the safety and efficacy of incretin 
therapy in T2DM.52 The results from this analysis showed that 
the most common side effects of exenatide were nausea (57%) 
and vomiting (17%). The amount of nausea and vomiting was 
dose-dependent, usually mild to moderate in nature, lessened 
with dose titration, and most common during the initial weeks 
of therapy with a decline thereafter. Overall, 4% of patients 
withdrew from the studies because of gastrointestinal side 
effects.52 In addition, severe hypoglycemia associated with 
exenatide use was rare, reported in only five of 2781 patients 
in which all five patients also received a sulfonylurea. Mild 
to moderate hypoglycemia was noted in 16% of patients 
treated with exenatide versus 7% treated with placebo, and 
was again mostly occurred during co-administration with 
a sulfonylurea. Anti-exenatide antibodies were detected in 
41%–49% of patients in the treatment arms but were not 
associated with glycemic control.43–45
The most serious (but rare) potential adverse event of 
exenatide is pancreatitis. In May 2008, the United Kingdom 
Medicines and Healthcare Products Regulatory Agency 
(MHRA) noted 89 post-marketing cases of pancreatitis with 
87 of them occurring in the United States.53 In August 2008, 
the United States FDA reported six cases of hemorrhagic or 
necrotizing pancreatitis in exenatide-treated patients, and 
two of these patients died. In the exenatide clinical trials, 
the incident rate of pancreatitis was 1.79/1000 subject years 
for exenatide-treated patients, 1.35 for insulin comparator 
group, and 2.72 for placebo-treated patients.53 The company 
that markets exenatide also tabulated incident data for 
pancreatitis in patients with T2DM (from insurance claims 
database) and noted a three- to four-fold greater incidence 
of acute pancreatitis in subjects with T2DM compared to 
patients without diabetes.53 While no definite relationship 
has been established between exenatide and pancreatitis, the 
FDA has requested that information about acute pancreatitis 
be included in the precautions section.53
Exenatide and human β-cell function
Similar to GLP-1, short-term infusion of exenatide (5 hrs) 
has been shown to improve first- and second-phase insulin 
secretion in patients with T2DM.54 Thirty weeks of exenatide 
use also resulted in improved β-cell function based on 
mathematical modeling of β cell in response to test meal in 
patients with T2DM who were treated with metformin and/
or sulfonylurea.55 Furthermore, when compared to insulin 
glargine, exenatide treatment for 52 weeks significantly 
improved β-cell function as assessed by arginine-stimulated 
hyperglycemic clamp, and the β-cell function reverted to pre-
treatment levels after discontinuation of exenatide therapy.56
Liraglutide
Liraglutide is a GLP-1 analog with two modifications: 
a substitution of Arg34 for Lys34 and an attachment of a 
C-16 free-fatty acid derivative via a glutamoyl spacer to 
Lys26 (Figure 1). The free-fatty acid derivative is thought 
to promote noncovalent binding of liraglutide to albumin; 
therefore, the absorption rate of liraglutide is delayed from 
the injection site and the rate of renal clearance of liraglutide 
is also slowed.57
Pharmacology
Like GLP-1 and exenatide, liraglutide must be injected 
subcutaneously. Peak plasma concentrations are detected 
10–14 hrs after injection, and the half-life is about 
11–13 hrs.58,59
Efficacy studies
The LEAD® programme (Liraglutide Effect and Action in 
Diabetes) is the Phase 3 clinical trial of liraglutide involving 
five randomized, controlled, double-blind studies that 
included about 4,000 patients with T2DM. Results from two 
of the studies have recently been published in peer-reviewed 
journals and the results from two other studies have been 
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The LEAD-3 Mono study is a double-blind, double-dummy, 
active-controlled, parallel-group study in which 746 patients 
with T2DM (previously treated with diet or oral hypoglycemic 
agent monotherapy) were randomized to receive liraglutide 
1.2 mg, liraglutide 1.8 mg, or glimepiride 8mg once daily 
(Table 2).60 Patients on oral hypoglycemic agent monotherapy 
had their treatment discontinued at randomization. At the 
end of 52 weeks, a significant reduction in HbA1c was 
observed in all groups: 0.5% with glimepiride, 0.8% with 
liraglutide 1.2 mg, and 1.1% with liraglutide 1.8 mg. Signifi-
cant reduction in fasting plasma glucose was also observed 
with an average reduction of 0.3 mmol/L, 0.8 mmol/L, and 
1.4 mmol/L in the glimepiride 8 mg, liraglutide 1.2 mg, and 
liraglutide 1.8 mg groups, respectively. Furthermore, the 
percentage of patients who achieved a HbA1c of less than 7% 
was 28%, 43%, and 51% in the glimepiride 8 mg, liraglutide 
1.2 mg, and liraglutide 1.8mg groups, respectively. Patients 
on liraglutide also lost weight of about 1.9 kg and 2.3 kg in 
the liraglutide 1.2 mg and 1.8 mg groups, respectively, while 
those on glimepiride 8 mg gained about 1.2 kg.60
The LEAD-2 study is a 26-week, double-blind, double-
dummy, placebo- and active-controlled, parallel-group clinical 
trial in which 1091 patients with T2DM were randomized 
to liraglutide once daily (either 0.6 mg, 1.2 mg, or 1.8 mg), 
glimepiride 4 mg once daily, or placebo, all in combination 
with metformin (1 gm twice daily) (Table 2).61 All other oral 
hypoglycemic agents were discontinued at randomization. 
After 26 weeks, HbA1c was reduced by 1.0% in the liraglutide 
1.2 mg/metformin, the liraglutide 1.8 mg/metformin, and 
the glimepiride/metformin groups; decreased by 0.7% in the 
liraglutide 0.6 mg/metformin group; and increased by 0.1% in 
the placebo/metformin group. The percentage of participants 
who achieved HbA1c of less than 7% was 28%, 35%, and 
42% for the liraglutide/metformin groups (0.6 mg, 1.2 mg, 
1.8 mg, respectively), 36% for the glimepiride/metformin 
group, and 11% for the placebo/metformin group. Fasting 
plasma glucose was decreased by 1.1 mmol/L, 1.6 mmol/L, 
1.7 mmol/L in the liraglutide/metformin groups (0.6, 1.2, and 
1.8 mg of liraglutide, respectively) compared to a reduction 
of 1.3 mmol/L in the glimepiride/metformin group and an 
increase of 0.4 mmol/L in the placebo/metformin group. 
Weight loss was also noted in the liraglutide/metformin 
groups in a dose-dependent fashion; weight reduction of 
1.8 kg, 2.6 kg, and 2.8 kg for the liraglutide/metformin groups 
(liraglutide 0.6 mg, 1.2 mg, and 1.8 mg, respectively), which 
was significantly greater than the 1.5 kg weight loss noted 
in the placebo/metformin group. The glimepiride/metformin 
group had a 1.0 kg weight gain.61
In another 26-week, randomized, double-dummy, 
placebo-controlled study, 1041 subjects were randomized to 
five different arms: liraglutide (0.6 mg, 1.2 mg, or 1.8 mg) once 
daily added to glimepiride once daily, placebo/glimepiride 
2–4 mg daily, or rosiglitazone 4 mg/glimepiride combination 
once daily (Table 2).62 HbA1c reduction of 0.6%, 1.1%, and 
1.1%, were seen in the liraglutide (0.6 mg, 1.2 mg, 1.8 mg)/
glimepiride groups, respectively. An HbA1c reduction of 0.4% 
was noted in the rosiglitazone/glimepiride group, and a 0.2% 
HbA1c increase was noted in the placebo/glimepiride group. 
The percentage of participants who achieved HbA1c of less 
than 7% was 24%, 35%, and 42% in the liraglutide (0.6 mg, 
1.2 mg, and 1.8 mg)/glimepiride groups, respectively, 8% in 
the placebo/glimepiride group, and 22% in the rosiglitazone/
glimepiride group. Weight gain of 0.7 kg, 0.3 kg, and 2.1 kg 
was noted in the liraglutide 0.6 mg/glimepiride, liraglu-
tide 1.2 mg/glimepiride, and the rosiglitazone/glimepiride 
groups, respectively, while a weight reduction of 0.2 kg and 
0.1 kg was noted in the liraglutide 1.8 mg/glimepiride group 
and the placebo/glimepiride group, respectively. Fasting 
plasma glucose was reduced by 0.7 mmol/L, 1.6 mmol/L, 
1.6 mmol/L in the liraglutide (0.6 mg, 1.2 mg, 1.8 mg)/
glimepiride groups, respectively, reduced by 0.9 mmol/L 
in the rosiglitazone/glimepiride group, and increased by 
1.0 mmol/L in the placebo/glimepiride group.62
In another 26-week randomized clinical trial, 581 subjects 
with T2DM were randomized to 1.8 mg liraglutide, placebo, or 
insulin glargine (open label) once daily as add-on to metformin 
1 gm twice daily plus glimepiride 2–4 mg once daily (Table 2).63 
HbA1c reduction of 1.3%, 0.2%, and 1.1% was noted in 
the liraglutide/metformin/glimepiride, placebo/metformin/
glimepiride, and glargine/metformin/glimepiride groups, 
respectively. Fasting plasma glucose reduction of 1.6 mmol/L 
and 1.8 mmol/L were noted in the liraglutide/metformin/
glimepiride and glargine/metformin/glimepiride groups while 
an increased of 0.5 mmol/L was noted in the placebo/metformin/
glimepiride group. Furthermore, weight reduction of 1.8 kg, 
0.4 kg was noted in the liraglutide/metformin/glimepiride and 
placebo/metformin/glimepiride groups, and weight increased 
of 1.6 kg was reported in the glargine/metformin/glimepiride 
group. The percentage of subjects who achieved HbA1c of 
less than 6.5% was 37%, 11%, and 24% in the liraglutide/
metformin/glimepiride, placebo/metformin/glimepiride, and 
glargine/metformin/glimepiride groups, respectively.63
Safety and tolerability
Similar to exenatide, the most frequently report adverse 
events for liraglutide were nausea and vomiting, especially Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 44
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at the higher doses.52 In the LEAD-2 study, hypoglycemia 
was noted in 3% of the liraglutide/metformin and placebo/
metformin groups compared to 17% in the glimepiride/
metformin group. Nausea was reported to occur in 11%–19% 
of the liraglutide/metformin groups in a dose-dependent 
fashion compared to 3%–4% in the placebo/metformin 
and glimepiride/metformin groups. Nausea was noted 
to decrease over the duration of the study. There were 
two cases of pancreatitis reported, one in the liraglutide 
1.2 mg group and one in the glimepiride group, and both 
recovered.61 In the LEAD-3 study, 12% and 8% of the 
liraglutide groups (1.2 mg and 1.8 mg, respectively) versus 
24% of the glimepiride group suffered mild hypoglycemia. 
Nausea was reported in 28% and 29% of the subjects in 
the liraglutide groups (1.2 mg and 1.8 mg, respectively), 
and 9% of the glimepiride group. Again, the incidence of 
nausea decreased over time. Two participants, one each 
in the 1.2 mg and 1.8 mg liraglutide groups, developed 
pancreatitis during the study and both recovered.60 In one 
of the 26-week studies, 9%–13% of the liraglutide treated 
subjects developed antibodies to liraglutide. Nausea was 
reported in 5%–11% of the liraglutide/glimepiride groups, 
2% of the placebo/glimepiride group, and 3% of the rosi-
glitzaone/glimepiride.62 In another 26-week study, 10% of 
the subjects in the liraglutide group developed liraglutide 
antibodies.63 Nausea was reported in 14%, 4%, and 1% of the 
subjects in the liraglutide/metformin/glimepiride, placebo/
metformin/glimepiride, and glargine/metformin/glimepiride 
groups.63 Hypoglycemia was reported in 27%, 17%, and 
29% of the subjects in the liraglutide/metformin/glimepiride, 
placebo/metformin/glimepiride, and glargine/metformin/
glimepiride groups.63
Liraglutide and human β cell function
In patients with T2DM, a single dose of liraglutide was able 
to improve β-cell sensitivity to glucose.64 Two different stud-
ies have demonstrated that treatment of patients with T2DM 
with liraglutide for seven days improved β-cell function as 
assessed by a model using multiple-meal tests, arginine 
stimulation test, and hyperglycemic clamp.65,66
Exenatide long-acting release (LAr)
Exenatide LAR is formulated with exenatide and poly 
(d,l lactic-co-glycolic acid) microspheres, a biodegradable 
medical polymer commonly used in extended drug release 
formulation.67 Once weekly subcutaneous injection is thought 
to be the desired frequency, and it is currently undergoing 
phase 3 clinical trials.
Pharmacology
With a weekly injection of 2 mg exenatide LAR, a therapeutic 
plasma level of 50 pg/mL was reached after the second 
injection. The steady state concentration of exenatide LAR 
(232 pg/mL) was reached by week 6. This level is similar 
to the peak level reached by a single injection of 10 µg of 
exenatide. After 15 weeks of treatment with exenatide LAR, 
no more injections were given, and its concentration gradually 
decreased to below therapeutic level by week 21.68
Efficacy studies
In a randomized, placebo-controlled, phase 2 study, 
45 patients with T2DM sub-optimally controlled by 
metformin and/or diet and exercise were randomized 
to exenatide LAR 0.8 mg, exenatide LAR 2.0 mg, or placebo 
LAR once weekly for 15 weeks (Table 3).68 Subjects who 
were on metformin continued at the same dose. Exenatide 
LAR reduced HbA1c by 1.4% and 1.7% in the exenatide 
LAR 0.8 mg and 2.0 mg groups, respectively, compared to 
an increase of 0.4% in the placebo group. The percentage 
of subjects who achieved HbA1c of less than 7% was 36% 
and 86% for the exenatide LAR 0.8 mg and 2.0 mg groups, 
respectively, and no change in HbA1c was noted for the 
placebo group. Fasting plasma glucose was reduced by 
2.4 mmol/L and 2.2 mmol/L in the exenatide LAR 0.8 mg 
and 2.0 mg groups, respectively, compared to an increase of 
1.0 mmol/L in the placebo group. Subjects in the exenatide 
LAR 2.0 mg group lost an average weight of 3.8 kg while 
those in the exenatide LAR 0.8 mg and placebo groups did 
not have any change in weight.68
In a 30-week, randomized, open-label, comparator-
controlled, noninferiority study, exenatide LAR 2mg once 
weekly was compared to exenatide 10 µg twice daily 
in 295 patients with T2DM treated by diet, metformin, 
sulfonylurea, thiazolidinedione, or any combination of the 
two agents (Table 3).67 Patients on exenatide LAR has HbA1c 
reduction of 1.9% compared to 1.5% reduction in the exena-
tide twice daily group. Furthermore, 77% of the subjects in 
the exenatide LAR group achieved HbA1c of less than 7% 
compared to 61% of the exenatide twice daily group. Weight 
reduction was comparable in that subjects in the exenatide 
LAR group lost 3.7 kg while subjects given exenatide twice 
daily lost 3.6 kg of weight. Fasting plasma glucose was also 
significantly reduced by 2.3 mmol/L in the exenatide LAR 
group compared to 1.4 mmol/L in the exenatide twice daily 
group. Fasting plasma glucagon levels were also significantly 
lower in the exenatide LAR-treated group compared to the 
placebo group.67Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 46
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Safety and tolerability
In the phase 2 study, 19% and 27% of the exenatide LAR 
0.8 mg and 2.0 mg groups, respectively, experienced nausea 
compared to 15% in the placebo group.68 Twenty-five 
percent of the subjects in the exenatide LAR 0.8 mg group 
experienced hypoglycemia with only one case confirmed 
by blood glucose concentration (3.1 mmol/L), while the 
exenatide LAR 2.0 mg and placebo groups did not report 
any hypoglycemia.68 Sixty-seven percent of the subjects in 
the exenatide LAR groups developed positive anti-exenatide 
antibodies after 15 weeks.68 In the 30-week randomized trial, 
anti-exenatide antibody levels were higher with exenatide 
LAR versus the exenatide twice daily group.67 The antibody 
titers seems to declined progressively after 16 weeks of 
treatment.67 Nausea was reported in 26% of the exenatide 
LAR group compared to 35% of the exenatide twice daily 
group, while vomiting was reported in 11% of the exena-
tide LAR group compared to 19% of the exenatide twice 
daily group. Injection site pruritus was also much more 
frequent (18%) in the exenatide LAR group compared to the 
exenatide twice daily group (1%).67 No cases of pancreatitis 
were reported in either of the studies involving exenatide 
and exenatide LAR.67
Other GLP-1r agonists under 
development
There are other GLP-1R agonists currently under clinical 
development that are anticipated to have longer half-lives 
and presumably less gastrointestinal side effects. LY2189265 
is a GLP-1 analog-Fc fusion protein, and LY2428757 is a 
pegylated GLP-1 analog, both can be administered just once 
weekly.69 CJC-1134-PC is a recombinant human serum 
albumin-exendin-4 conjugated protein that has a half-life 
of approximately eight days and Albiglutide is an albumin-
GLP-1 protein complex, both can be administered once 
weekly.70–72 NN9535 is another long-acting human GLP-1 
analog designed for once weekly injection using protein-
acylation technology.73 Taspoglutide and AVE0010 are two 
other GLP-1R agonists currently undergoing clinical trials.74,75 
An oral formulation of a GLP-1R agonist is reportedly also 
under development.76 The compounds mentioned here are just 
a few representations of the GLP-1R agonists under clinical 
development, and are by no means comprehensive. Few data 
are publically available regarding these compounds.
Conclusions
GLP-1R agonists are a new class of hypoglycemic agents 
that have generated a lot of interests in the field of diabetes. 
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The development of GLP-1R agonists started with their 
potential as insulin secretagogues. Exogenous administration 
of GLP-1 and GLP-1R agonists at pharmacological doses 
showed that they not only have insulinotropic effect, but also 
effects on suppressing glucagon secretion in the presence 
of hyperglycemia, delaying post-prandial gastric emptying, 
inducing satiety, and promoting weight loss over prolonged 
administration–all of which work in synergy to normalize 
glucose homeostasis in patients with T2DM. Furthermore, 
GLP-1R agonists were noted to increase insulin synthesis, 
increase islet cell turnover, and decrease β cell apoptosis 
in animals–properties that may help slow the progression 
or even reverse the course of diabetes. Indirect measures 
of β-cell function showed that GLP-1R agonists improved 
β-cell responsiveness to glucose as well as first- and 
second-phase insulin secretion. However, the improvement 
in β-cell functions reverted back to pre-treatment levels after 
discontinuation of therapy, at least in the case of exenatide. 
Nausea and vomiting are the common side effects during 
the initial weeks of therapy, which lessen with dose titra-
tion, and generally decline with continuous use. Patients 
with severe gastrointestinal diseases probably should not 
be started on GLP-1R agonists in case of development of 
pancreatitis. Long-term use of exenatide (data available up to 
three years) has shown sustained HbA1c reduction and weight 
loss, which are very encouraging because these effects have 
not been shown by any other class of hypoglycemic agents. 
GLP-1R agonists as treatment modalities for diabetes have 
a promising future, especially with their potential to help 
reverse or prevent diabetes.
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